IP waiver for COVID-19 vaccines is a misguided and ineffective response to a shared global challenge. In the long run, the waiver proposal undermines the existing vaccine eco-system built in the crisis urgency.

EuropaBio welcomes the in-depth opinion of the European Group on Ethics on the uses of genome editing and thanks the Group for raising the awareness of a technology which will enable the development of many solutions for healthy people and planet.